Integrative therapies and pediatric inflammatory bowel disease: The current evidence

Children

Volumn 1, Issue 2, 2014, Pages 149-165

  Misra, Sanghamitra M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acupuncture; Breastfeeding; Crohn s disease; Diet; Exercise; Helminths; Herbs; Inflammatory bowel disease; Probiotics; PUFAs; Relaxation; Ulcerative colitis

Indexed keywords

EID: 84994366022     PISSN: None     EISSN: 22279067     Source Type: Journal    
DOI: 10.3390/children1020149     Document Type: Review

References (86)

1. Mendeloff, A.I.; Calkins, B.M. The epidemiology of idiopathic inflammatory bowel disease. In Inflammatory Bowel Disease; Kirsner, J.B., Shorter, R.G., Eds.; Lea & Febiger: Philadelphia, PA, USA, 1988; p. 3.
2. Van Limbergen, J.; Russell, R.K.; Drummond, H.E.; Aldhous, M.C.; Round, N.K.; Nimmo, E.R.; Smith, L.; Gillett, P.M.; McGrogan, P.; Weaver, L.T.; et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008, 135, 1114–1122.
3. Vernier-Massouille, G.; Balde, M.; Salleron, J.; Turck, D.; Dupas, J.L.; Mouterde, O.; Merle, V.; Salomez, J.L.; Branche, J.; Marti, R.; et al. Natural history of pediatric Crohn’s disease: A population-based cohort study. Gastroenterology 2008, 135, 1106–1113.
4. Roth, M.P.; Petersen, G.M.; McElree, C.; Vadheim, C.M.; Panish, J.F.; Rotter, J.I. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology 1989, 96, 1016–1020.
5. Fielding, J.F. The relative risk of inflammatory bowel disease among parents and siblings of Crohn’s disease patients. J. Clin. Gastroenterol. 1986, 8, 655–657.
6. Satsangi, J.; Grootscholten, C.; Holt, H.; Jewell, D.P. Clinical patterns of familial inflammatory bowel disease. Gut 1996, 38, 738–741.
7. Orholm, M.; Munkholm, P.; Langholz, E.; Nielsen, O.H.; Sørensen, T.I.; Binder, V. Familial occurrence of inflammatory bowel disease. N. Engl. J. Med. 1991, 324, 84–88.
8. Peeters, M.; Nevens, H.; Baert, F.; Hiele, M.; de Meyer, A.M.; Vlietinck, R.; Rutgeerts, P. Familial aggregation in Crohn’s disease: Increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996, 111, 597–603.
9. Yang, H.; McElree, C.; Roth, M.P.; Shanahan, F.; Targan, S.R.; Rotter, J.I. Familial empirical risks for inflammatory bowel disease: Differences between Jews and non-Jews. Gut 1993, 34, 517–524.
10. Nunes, T.; Fiorino, G.; Danese, S.; Sans, M. Familial aggregation in inflammatory bowel disease: Is it genes or environment? World J. Gastroenterol. 2011, 17, 2715–2722.
11. Halfvarson, J.; Bodin, L.; Tysk, C.; Lindberg, E.; Järnerot, G. Inflammatory bowel disease in a Swedish twin cohort: A long-term follow-up of concordance and clinical characteristics. Gastroenterology 2003, 124, 1767–1773.
12. Thompson, N.P.; Driscoll, R.; Pounder, R.E.; Wakefield, A.J. Genetics versus environment in inflammatory bowel disease: Results of a British twin study. BMJ 1996, 312, 95–96.
13. Spehlmann, M.E.; Begun, A.Z.; Burghardt, J.; Lepage, P.; Raedler, A.; Schreiber, S. Epidemiology of inflammatory bowel disease in a German twin cohort: Results of a nationwide study. Inflamm. Bowel Dis. 2008, 14, 968–976.
14. Ananthakrishnan, A.N.; Higuchi, L.M.; Huang, E.S.; Khalili, H.; Richter, J.M.; Fuchs, C.S.; Chan, A.T. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: A cohort study. Ann. Intern. Med. 2012, 156, 350–359.
15. Korelitz, B.I.; Rajapakse, R.; Schwarz, S.; Horatagis, A.P.; Gleim, G. Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: A case-control study. Am. J. Gastroenterol. 2000, 95, 1949–1954.
16. Bernstein, C.N.; Singh, S.; Graff, L.A.; Walker, J.R.; Miller, N.; Cheang, M. A prospective population-based study of triggers of symptomatic flares in IBD. Am. J. Gastroenterol. 2010, 105, 1994–2002.
17. Radon, K.; Windstetter, D.; Poluda, A.L.; Mueller, B.; von Mutius, E.; Koletzko, S. Contact with farm animals in early life and juvenile inflammatory bowel disease: A case-control study. Pediatrics 2007, 120, 354–361.
18. Hlavaty, T.; Toth, J.; Koller, T.; Krajcovicova, A.; Oravcova, S.; Zelinkova, Z.; Huorka, M. Smoking, breastfeeding, physical inactivity, contact with animals, and size of the family influence the risk of inflammatory bowel disease: A Slovak case-control study. United European Gastroenterol. J. 2013, 1, 109–119.
19. Hafner, S.; Timmer, A.; Herfarth, H.; Rogler, G.; Schölmerich, J.; Schäffler, A.; Ehrenstein, B.; Jilg, W.; Ott, C.; Strauch, U.G.; et al. The role of domestic hygiene in inflammatory bowel diseases: Hepatitis A and worm infestations. Eur. J. Gastroenterol. Hepatol. 2008, 20, 561–566.
20. Bernstein, C.N.; Rawsthorne, P.; Cheang, M.; Blanchard, J.F. A population-based case control study of potential risk factors for IBD. Am. J. Gastroenterol. 2006, 101, 993–1002.
21. Shaw, S.Y.; Blanchard, J.F.; Bernstein, C.N. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am. J. Gastroenterol. 2010, 105, 2687–2692.
22. Wong, A.P.; Clark, A.L.; Garnett, E.A.; Acree, M.; Cohen, S.A.; Ferry, G.D.; Heyman, M.B. Use of complementary medicine in pediatric patients with inflammatory bowel disease: Results from a multicenter survey. J. Pediatr. Gastroenterol. Nutr. 2009, 48, 55–60.
23. Day, A.S.; Whitten, K.E.; Bohane, T.D. Use of complementary and alternative medicines by children and adolescents with inflammatory bowel disease. J. Paediatr. Child Health 2004, 40, 681–684.
24. Heuschkel, R.; Afzal, N.; Wuerth, A.; Zurakowski, D.; Leichtner, A.; Kemper, K.; Tolia, V.; Bousvaros, A. Complementary medicine use in children and young adults with inflammatory bowel disease. Am. J. Gastroenterol. 2002, 97, 382–388.
25. Nousiainen, P.; Merras-Salmio, L.; Aalto, K.; Kolho, K.L. Complementary and alternative medicine use in adolescents with inflammatory bowel disease and juvenile idiopathic arthritis. BMC Complement. Altern. Med. 2014, 14, 124.
26. Koletzko, S.; Sherman, P.; Corey, M.; Griffiths, A.; Smith, C. Role of infant feeding practices in development of Crohn’s disease in childhood. BMJ 1989, 298, 1617–1618.
27. Koletzko, S.; Griffiths, A.; Corey, M.; Smith, C.; Sherman, P. Infant feeding practices and ulcerative colitis in childhood. BMJ 1991, 302, 1580–1581.
28. Barclay, A.R.; Russell, R.K.; Wilson, M.L.; Gilmour, W.H.; Satsangi, J.; Wilson, D.C. Systematic review: The role of breastfeeding in the development of pediatric inflammatory bowel disease. J. Pediatr. 2009, 155, 421–426.
29. Vernia, P.; Loizos, P.; di Giuseppantonio, I.; Amore, B.; Chiappini, A.; Cannizzaro, S. Dietary calcium intake in patients with inflammatory bowel disease. J. Crohns Colitis 2014, 1, 312–317.
30. Brasil Lopes, M.; Rocha, R.; Castro Lyra, A.; Rosa Oliveira, V.; Gomes Coqueiro, F.; Silveira Almeida, N.; Santos Valois, S. Oliveira Santana GRestriction of dairy products: A reality in inflammatory bowel disease patients. Nutr. Hosp. 2014, 29, 575–581.
31. Gottschall, E. Science behind the diet. Available online: http://www.breakingtheviciouscycle.info/p/science-behind-the-diet/(accessed on 4 August 2014).
32. Suskind, D.L.; Wahbeh, G.; Gregory, N.; Vendettuoli, H.; Christie, D. Nutritional therapy in pediatric Crohn disease: The specific carbohydrate diet. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 87–91.
33. Cohen, S.A.; Gold, B.D.; Oliva, S.; Lewis, J.; Stallworth, A.; Koch, B.; Eshee, L.; Mason, D. Clinical and mucosal improvement with the specific carbohydrate diet in Pediatric Crohn’s Disease: A prospective pilot study. J. Pediatr. Gastroenterol. Nutr. 2014, PMID: 24897165.
34. Nahidi, L.; Day, A.S.; Lemberg, D.A.; Leach, S.T. Paediatric inflammatory bowel disease: A mechanistic approach to investigate exclusive enteral nutrition treatment. Scientifica 2014, doi:10.1155/2014/423817.
35. De Bie, C.; Kindermann, A.; Escher, J. Use of exclusive enteral nutrition in paediatric Crohn’s disease in The Netherlands. J. Crohns Colitis 2013, 7, 263–270.
36. Knight, C.; El-Matary, W.; Spray, C.; Sandhu, B.K. Long-term outcome of nutritional therapy in paediatric Crohn’s disease. Clin. Nutr. 2005, 24, 775–779.
37. Heuschkel, R.B.; Menache, C.C.; Megerian, J.T.; Baird, A.E. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J. Pediatr. Gastroenterol. Nutr. 2000, 31, 8–15.
38. Dziechciarz, P.; Horvath, A.; Shamir, R.; Szajewska, H. Meta-analysis: Enteral nutrition in active Crohn’s disease in children. Aliment. Pharmacol. Ther. 2007, 26, 795–806.
39. Sonnenberg, A. Geographic variation in the incidence of and mortality from inflammatory bowel disease. Dis. Colon Rectum 1986, 29, 854–861.
40. Socha, P.; Ryzko, J.; Koletzko, B.; Celinska-Cedro, D.; Woynarowski, M.; Czubkowski, P.; Socha, J. Essential fatty acid depletion in children with inflammatory bowel disease. Scand. J. Gastroenterol. 2005, 40, 573–577.
41. Uchiyama, K.; Nakamura, M.; Odahara, S.; Koido, S.; Katahira, K.; Shiraishi, H.; Ohkusa, T.; Fujise, K.; Tajiri, H. N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2010, 16, 1696–1707.
42. Turner, D.; Shah, P.S.; Steinhart, A.H.; Zlotkin, S.; Griffiths, A.M. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): A systematic review and meta-analyses. Inflamm. Bowel Dis. 2011, 17, 336–345.
43. Cabré, E.; Mañosa, M.; Gassull, M.A. Omega-3 fatty acids and inflammatory bowel diseases—A systematic review. Br. J. Nutr. 2012, 107, S240–S252.
44. Shadnoush, M.; Shaker Hosseini, R.; Mehrabi, Y.; Delpisheh, A.; Alipoor, E.; Faghfoori, Z.; Mohammadpour, N.; Zaringhalam Moghadam, J. Probiotic yogurt affects pro-and anti-inflammatory factors in patients with inflammatory bowel disease. Iran J. Pharm. Res. 2013, 12, 929–936.
45. Ishikawa, H.; Akedo, I.; Umesaki, Y.; Tanaka, R.; Imaoka, A.; Otani, T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J. Am. Coll. Nutr. 2003, 22, 56–63.
46. Zocco, M.A.; dal Verme, L.Z.; Cremonini, F.; Piscaglia, A.C.; Nista, E.C.; Candelli, M.; Novi, M.; Rigante, D.; Cazzato, I.A.; Ojetti, V.; et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 2006, 23, 1567–1574.
47. Miele, E.; Pascarella, F.; Giannetti, E.; Quaglietta, L.; Baldassano, R.N.; Staiano, A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol. 2009, 104, 437–443.
48. Huynh, H.Q.; deBruyn, J.; Guan, L.; Diaz, H.; Li, M.; Girgis, S.; Turner, J.; Fedorak, R.; Madsen, K. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot study. Inflamm. Bowel Dis. 2009, 15, 760–768.
49. Shen, J.; Zuo, Z.X.; Mao, A.P. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: Meta-analysis of randomized controlled trials. Inflamm. Bowel Dis. 2014, 20, 21–35.
50. Dieleman, L.; Hoentjen, F. Probiotics have a limited role in the treatment of inflammatory bowel disease. Ned. Tijdschr. Geneeskd. 2012, 156, A5206.
51. Ruemmele, F.M.; Veres, G.; Kolho, K.L.; Griffiths, A.; Levine, A.; Escher, J.C.; Amil Dias, J.; Barabino, A.; Braegger, C.P.; Bronsky, J.; et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J. Crohns Colitis 2014, doi:10.1016/j.crohns.2014.04.005.
52. Perez, M.E.; Youssef, N.N. Dyspepsia in childhood and adolescence: Insights and treatment considerations. Curr. Gastroenterol. Rep. 2007, 9, 447–455.
53. Joos, S.; Rosemann, T.; Szecsenyi, J.; Hahn, E.G.; Willich, S.N.; Brinkhaus, B. Use of complementary and alternative medicine in Germany—A survey of patients with inflammatory bowel disease. BMC Complement. Altern. Med. 2006, 6, 19.
54. Gupta, I.; Parihar, A.; Malhotra, P.; Singh, G.B.; Lüdtke, R.; Safayhi, H.; Ammon, H.P. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur. J. Med. Res. 1997, 2, 37–43.
55. Gerhardt, H.; Seifert, F.; Buvari, P.; Vogelsang, H.; Repges, R. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z. Gastroenterol. 2001, 39, 11–17.
56. Holtmeier, W.; Zeuzem, S.; Preiss, J.; Kruis, W.; Böhm, S.; Maaser, C.; Raedler, A.; Schmidt, C.; Schnitker, J.; Schwarz, J.; et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn’s disease: Good safety profile but lack of efficacy. Inflamm. Bowel Dis. 2011, 17, 573–582.
57. Langmead, L.; Feakins, R.M.; Goldthorpe, S.; Holt, H.; Tsironi, E.; de Silva, A.; Jewell, D.P.; Rampton, D.S. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment. Pharmacol. Ther. 2004, 19, 739–747.
58. Choudhary, M.; Kochhar, A.; Sangha, J. Hypoglycemic and hypolipidemic effect of Aloe vera L. in non-insulin dependent diabetics. J. Food Sci. Technol. 2014, 51, 90–96.
59. Yang, H.N.; Kim, D.J.; Kim, Y.M.; Kim, B.H.; Sohn, K.M.; Choi, M.J.; Choi, Y.H. Aloe-induced toxic hepatitis. J. Korean Med. Sci. 2010, 25, 492–495.
60. Holt, P.R.; Katz, S.; Kirshoff, R. Curcumin therapy in inflammatory bowel disease: A pilot study. Dig. Dis. Sci. 2005, 50, 2191–2193.
61. Hanai, H.; Iida, T.; Takeuchi, K.; Watanabe, F.; Maruyama, Y.; Andoh, A.; Tsujikawa, T.; Fujiyama, Y.; Mitsuyama, K.; Sata, M.; et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 2006, 4, 1502–1506.
62. Suskind, D.L.; Wahbeh, G.; Burpee, T.; Cohen, M.; Christie, D.; Weber, W. Tolerability of curcumin in pediatric inflammatory bowel disease: A forced-dose titration study. J. Pediatr. Gastroenterol. Nutr. 2013, 56, 277–279.
63. Slonim, A.E.; Grovit, M.; Bulone, L. Effect of exclusion diet with nutraceutical therapy in juvenile Crohn’s disease. J. Am. Coll. Nutr. 2009, 28, 277–285.
64. Langmead, L.; Dawson, C.; Hawkins, C.; Banna, N.; Loo, S.; Rampton, D.S. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: An in vitro study. Aliment. Pharmacol. Ther. 2002, 16, 197–205.
65. Ng, S.C.; Lam, Y.T.; Tsoi, K.K.; Chan, F.K.; Sung, J.J.; Wu, J.C. Systematic review: The efficacy of herbal therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2013, 38, 854–863.
66. Ruyssers, N.E.; de Winter, B.Y.; de Man, J.G.; Loukas, A.; Herman, A.G.; Pelckmans, P.A.; Moreels, T.G. Worms and the treatment of inflammatory bowel disease: Are molecules the answer? Clin. Dev. Immunol. 2008, doi:10.1155/2008/567314.
67. Summers, R.W.; Elliott, D.E.; Qadir, K.; Urban, J.F., Jr.; Thompson, R.; Weinstock, J.V. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am. J. Gastroenterol. 2003, 98, 2034–2041.
68. Joos, S.; Wildau, N.; Kohnen, R.; Szecsenyi, J.; Schuppan, D.; Willich, S.N.; Hahn, E.G.; Brinkhaus, B. Acupuncture and moxibustion in the treatment of ulcerative colitis: A randomized controlled study. Scand. J. Gastroenterol. 2006, 41, 1056–1063.
69. Joos, S.; Brinkhaus, B.; Maluche, C.; Maupai, N.; Kohnen, R.; Kraehmer, N.; Hahn, E.G.; Schuppan, D. Acupuncture and moxibustion in the treatment of active Crohn’s disease: A randomized controlled study. Digestion 2004, 69, 131–139.
70. Ji, J.; Lu, Y.; Liu, H.; Feng, H.; Zhang, F.; Wu, L.; Cui, Y.; Wu, H. Acupuncture and moxibustion for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials. Evid. Based Complement. Alternat. Med. 2013, 2013, 158352.
71. Cotton, S.; Humenay Roberts, Y.; Tsevat, J.; Britto, M.T.; Succop, P.; McGrady, M.E.; Yi, M.S. Mind-body complementary alternative medicine use and quality of life in adolescents with inflammatory bowel disease. Inflamm. Bowel Dis. 2010, 16, 501–506.
72. Timmer, A.; Preiss, J.C.; Motschall, E.; Rücker, G.; Jantschek, G.; Moser, G. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst. Rev. 2011, doi:10.1002/14651858.CD006913.pub2.
73. Mizrahi, M.C.; Reicher-Atir, R.; Levy, S.; Haramati, S.; Wengrower, D.; Israeli, E.; Goldin, E. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychol. Health 2012, 27, 1463–1479.
74. McCormick, M.; Reed-Knight, B.; Lewis, J.D.; Gold, B.D.; Blount, R.L. Coping skills for reducing pain and somatic symptoms in adolescents with IBD. Inflamm. Bowel Dis. 2010, 16, 2148–2157.
75. Grootenhuis, M.A.; Maurice-Stam, H.; Derkx, B.H.; Last, B.F. Evaluation of a psychoeducational intervention for adolescents with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2009, 21, 430–435.
76. Thompson, R.D.; Craig, A.; Crawford, E.A.; Fairclough, D.; Gonzalez-Heydrich, J.; Bousvaros, A.; Noll, R.B.; DeMaso, D.R.; Szigethy, E. Longitudinal results of cognitive behavioral treatment for youths with inflammatory bowel disease and depressive symptoms. J. Clin. Psychol. Med. Settings 2012, 19, 329–337.
77. Almadani, S.B.; Adler, J.; Browning, J.; Green, E.H.; Helvie, K.; Rizk, R.S. Zimmermann EM effects of inflammatory bowel disease on students’ adjustment to college. Clin. Gastroenterol. Hepatol. 2014, doi:10.1016/j.cgh.2014.03.032.
78. Jowett, S.L.; Seal, C.J.; Barton, J.R.; Welfare, M.R. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am. J. Gastroenterol. 2001, 96, 2921–2928.
79. Gallo, J.; Grant, A.; Otley, A.R.; Orsi, M.; MacIntyre, B.; Gauvry, S.; Lifschitz, C. Do parents and children agree? Quality-of-life assessment of children with inflammatory bowel disease and their parents. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 481–485.
80. Simrén, M.; Axelsson, J.; Gillberg, R.; Abrahamsson, H.; Svedlund, J.; Björnsson, E.S. Quality of life in inflammatory bowel disease in remission: The impact of IBS-like symptoms and associated psychological factors. Am. J. Gastroenterol. 2002, 97, 389–396.
81. Iskandar, H.N.; Cassell, B.; Kanuri, N.; Gyawali, C.P.; Gutierrez, A.; Dassopoulos, T.; Ciorba, M.A.; Sayuk, G.S. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J. Clin. Gastroenterol. 2014, 48, 423–429.
82. Mikocka-Walus, A.A.; Turnbull, D.A.; Moulding, N.T.; Wilson, I.G.; Andrews, J.M.; Holtmann, G.J. Antidepressants and inflammatory bowel disease: A systematic review. Clin. Pract. Epidemiol. Ment. Health 2006, 2, 1–9.
83. Moser, G. The role of hypnotherapy for the treatment of inflammatory bowel diseases. Expert Rev. Gastroenterol. Hepatol. 2014, 8, 601–606.
84. Nathan, I.; Norton, C.; Czuber-Dochan, W.; Forbes, A. Exercise in individuals with inflammatory bowel disease. Gastroenterol. Nurs. 2013, 36, 437–442.
85. Werkstetter, K.J.; Ullrich, J.; Schatz, S.B.; Prell, C.; Koletzko, B.; Koletzko, S. Lean body mass, physical activity and quality of life in paediatric patients with inflammatory bowel disease and in healthy controls. J. Crohns Colitis 2012, 6, 665–673.
86. Cosnes, J. Smoking, physical activity, nutrition and lifestyle: Environmental factors and their impact on IBD. Dig. Dis. 2010, 28, 411–417.